The need for new anti-hepatitis C virus therapeutic strategies: Targeting the cellular micro-ribonucleic acids?

Research output: Contribution to journalReview article

1 Citation (Scopus)


Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.

Original languageEnglish
Pages (from-to)312-317
Number of pages6
JournalSultan Qaboos University Medical Journal
Issue number3
Publication statusPublished - Dec 1 2010



  • Hepatitis C virus
  • Infection
  • Interferon
  • Liver
  • MicroRNAs
  • Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this